GENE

Genetic Technologies Share Price - GENE

2.28
-0.01 (-0.44%)
Upgrade to Real-Time
Afterhours (Closed)
2.29
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Genetic Technologies Ltd GENE NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.06 -2.55% 2.29 2.25 2.42 2.39 2.35 19:53:17
Bid Price Ask Price Spread Spread % News
2.28 2.34 0.06 2.56% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
1,655 555,442  2.35  1,306,836 1,257,247
Last Trade Time Type Quantity Stock Price Currency
19:45:38 50  2.28 USD

Genetic Technologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 27.53M 12.02M 12.02M  17.87k  - -0.94 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Genetic Technologies

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GENE Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Genetic Technologies Ltd is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.